Corporate P rese ntation December 2020 NASDAQ/TASE: M DGS Filed pursuant to R ule 433 of the Securities Ac t of 1933 Issuer F ree Writing Prospectus dated December 30, 2020 Relating to the Pre liminary P rospectus dated November 30, 2020 Registr ation Stateme nt File No. 333-249797

Forward Looking Statements This presentation may contain sta tem ents about Medigus Ltd. and its subsidiaries ( “ the Company ” ) that are “ Forward - Looking S tatements, ” whic h are based upon the cur rent e stim ates, assumptions and expectations of the Company ’ s management and its knowledge of the relevant m arket, including but not lim ited to statem ents regarding anticipated development and com mercialization ac tivities and mar ket opportunities. The Company ha s tried, where possible, to identify such inf orm ation and statem ents by using words such as “ anticipate, ” “ believe,...

This presentation highlights ba sic inform ation about us a nd the offering to which this presentation relate s. Beca use it is a sum mary, it does not contain all of the inf orm ation that you should consider before investing in our sec urities. The C om pany has filed a Registration Sta tem ent on Form F - 1 , a s amended (File No. 333 - 249797 ) ( including a prospec tus, which curre ntly is in preliminary f orm ) with the SEC for the offer ing to whic h this presentation re lates. The Registration Statement has not yet become effecti ve. B efore you inve st, you should read the Pr elimina...

Issuer Medigus Exchange & Ticker Nasdaq: MDGS Share s Off ered Up to 5,915,409 ADSs Over - Allotment Option 15% for 45 Days Offering S tructure ADS s Use of Proceeds Ge ner al cor porate pur poses and Working Capital S ole Bookr unning Manager Aegis C apital Corp. Offering Highlights

Investment Highlights NASDAQ/TAS E: M DGS Medigus is focuse d on developing and commerc ializ ing innovative technologies that have high growth potential Portfolio includes products developed at Me digus, its majority - owned subsidiaries and entities in whic h it holds minority ownership positions

Business Strategy Me digus engage d in advanc e medical solutions and innovative technologies both within the com pa ny and through its par tner c ompanie s Foc used on identifying, in - licensing, developing and c omm ercializing high - gr owth potential technologies

B usiness Model Tec hnology Oriente d Provides maximum fle xibility, allowing Company to develop a br oad a rray of new technologies. Streamlined Corporate Struc ture M anagem ent with e xtensive expe rience in str ucturing deals e nables the C om pany to quickly take advantage of tim e - sensitive opportunities and provide a range of business options. Collaboration Teamwork between M edigus e mployee s and those of the partner companies allows for leveraging of skills and expe rtise from dedicate d workforce to ensure success. Designed for maximum flexibility, allowing the C om pany to develop,...

Partner Companies: Mutually Benefic ial Re lationships *binding agreement had be en signed, no c losing ye t

Custom Visualization Solutions Sc outCam is a global leader in providing innovative, custom - tailored visualization solutions thr ough sma ll and highly resistant cameras a nd supple mentary technologies Working to improve perf orm anc e by enhancing the visual technological capabilities of organizations across various industries Cultivates partnerships for both research a nd development and multi - year m anufac turing contra cts Existing and upcoming contrac ts with Fortune 500 international partne rs Medigus owns 48.28% shar e

As c ameras become sma ller and more accessible, the incorpor ation of innovative visualization technologies ha s increased across industr ies. World’ s Smallest Cam eras Size Down to 1 mm outer diameter High Resolution With brillia nt image quality Close Minima l Foc us Distance down to 2 mm Water proof Extrem ely Lightweight Down to 0.04g per camer a RF Prote cted Wireless Zero latenc y Wired Up to 30 m Extreme Resistanc e • Extreme tem pera ture ( - 127 ˚C to 100 ˚C) • Vibrations • Vacuum • Radi

P roprieta ry Te chnologies All - inclusive, in - house technology C om ponents Additions Inte gra tions • Micro CMOS Sensors • Optics Design • Video Processors • Illumina tion • Long Lightweight Cables • Ultr asound Option • Endoscopes & Borescopes • Ta sk Specific Tools • High R esist

Potential Industr ies Se rved M EDIC AL Global Leader A.M. Sur gical AER OS PACE NAS A INDUSTRY R olls R oyce Are va Westinghouse Rolex S EC UR ITY & DEFENS E IDF Raf ael Isr aeli S ecret Ser vice C apable of withstanding the rigorous demands of aerospace Minimally inva sive ‘ c hip - on - tip ’ technology optimal for industry shift towards single - use endoscopy Custom - ta ilor ed to m eet custom er needs Built ready for any mission a nd environment

Online Event Platform

A S mart Tic keting Platfor m • Eventer enable s produce rs and venues to cr eate events, m ana ge ticket operations and billing, and promote ticket sale s all in one efficient and cost - productive platform • Eve nter generally r eceives 3 - 6 % commission f or tickets sold through Evente r ’ s platform • Fees for a dditional services like marketing and tailored features • Majority of ticket sales cur rently based in Israel • Intention to Expand to tar get m arke ts in North America • Sign a collabor ation agre ement with virtual event te chnology com pany, Screenz C ross Media Ltd. • Medigus...

Highlights 22,700 eve nts he ld to da te est. 2014 8,000 events held ( 2019 ) 1,000,000 ticke ts sold ( 2019 ) $ 26 MM in tickets sales ( 2019 ) + 118 % YOY over past five years

*binding agre ement in October 2020 , no closing yet *

Data - Driven E - commerc e Data - driven e - com merce te chnology com pany using AI and machine lear ning technologies to identify, ac quir e, a nd m aximize the sale s and profits of Fulfillment by Amaz on (F BA) businesses Currently managing 3 main brands, 2 FBA stores on 3 continents Upon closing, M edigus will potentially own 50.01 % of the share c apita l of SRP